U.S. markets closed
  • S&P Futures

    3,819.75
    -8.25 (-0.22%)
     
  • Dow Futures

    31,292.00
    -79.00 (-0.25%)
     
  • Nasdaq Futures

    12,750.50
    -81.25 (-0.63%)
     
  • Russell 2000 Futures

    2,178.50
    -21.50 (-0.98%)
     
  • Crude Oil

    62.95
    -0.58 (-0.91%)
     
  • Gold

    1,765.20
    -10.20 (-0.57%)
     
  • Silver

    27.27
    -0.41 (-1.50%)
     
  • EUR/USD

    1.2155
    -0.0031 (-0.26%)
     
  • 10-Yr Bond

    1.5180
    +0.1290 (+9.29%)
     
  • Vix

    28.89
    +7.55 (+35.38%)
     
  • GBP/USD

    1.3949
    -0.0064 (-0.45%)
     
  • USD/JPY

    106.1400
    -0.0900 (-0.08%)
     
  • BTC-USD

    47,042.79
    -3,381.71 (-6.71%)
     
  • CMC Crypto 200

    939.17
    -55.50 (-5.58%)
     
  • FTSE 100

    6,651.96
    -7.01 (-0.11%)
     
  • Nikkei 225

    29,292.83
    -875.44 (-2.90%)
     

Recap: Reata Pharmaceuticals Q3 Earnings

  • Oops!
    Something went wrong.
    Please try again later.
Benzinga Insights
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

 

Shares of Reata Pharmaceuticals (NASDAQ:RETA) rose 17.5% in pre-market trading after the company reported Q3 results.

Quarterly Results

Earnings per share were up 0.76% over the past year to ($1.31), which beat the estimate of ($1.98).

Revenue of $1,401,000 declined by 83.00% year over year, which beat the estimate of $1,270,000.

Guidance

Reata Pharmaceuticals hasn't issued any earnings guidance for the time being.

Reata Pharmaceuticals hasn't issued any revenue guidance for the time being.

How To Listen To The Conference Call

Date: Nov 09, 2020

View more earnings on RETA

Time: 08:30 AM

ET Webcast URL: https://edge.media-server.com/mmc/p/z6fgbcwf

Technicals

Company's 52-week high was at $257.96

Company's 52-week low was at $88.17

Price action over last quarter: Up 49.61%

Company Profile

Reata Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing therapeutics to address serious and life-threatening diseases by targeting molecular pathways. The company's product in the pipeline include bardoxolone methyl; Omaveloxolone and others.

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.